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Abstract: Impaired insulin secretion occurs early in the pathogenesis of type 2 diabetes mellitus 
(T2DM) and is chronic and progressive, resulting initially in impaired glucose tolerance (IGT) 
and eventually in T2DM. As most patients with T2DM have both insulin resistance and insulin 
deﬁ  ciency, therapy for T2DM should aim to control not only fasting, but also postprandial plasma 
glucose levels. While oral glucose-lowering treatment with metformin and thiazolidinediones 
corrects fasting plasma glucose, these agents do not address the problem of mealtime glucose 
spikes that have been shown to trigger atherogenic processes. Nateglinide is a derivative of the 
amino acid D-phenylalanine, which acts directly on the pancreatic β-cells to stimulate insulin 
secretion. Nateglinide monotherapy controls signiﬁ  cantly mealtime hyperglycemia and results 
in improved overall glycemic control in patients with T2DM by reducing glycosylated hemo-
globin (HbA1c) levels. The combination of nateglinide with insulin-sensitising agents, such as 
metformin and thiazolidinediones, targets both insulin deﬁ  ciency and insulin resistance and 
results in reductions in HbA1c that could not be achieved by monotherapy with other antidiabetic 
agents. In prediabetic subjects with IGT, nateglinide restores early insulin secretion and reduces 
postprandial hyperglycemia. Nateglinide has an excellent safety and tolerability proﬁ  le and 
provides a lifetime ﬂ  exibility that other antidiabetic agents could not accomplish. The aim of 
this review is to identify nateglinide as an effective “gate-keeper” in T2DM, since it restores 
early-phase insulin secretion and prevents mealtime glucose spikes throughout the day and to 
evaluate the results of ongoing research into its potential role in delaying the progression to 
overt diabetes and reducing its complications and mortality.
Keywords: nateglinide, type 2 diabetes mellitus, postprandial glycemia, impaired glucose 
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Introduction
Type 2 diabetes mellitus (T2DM) is characterized by chronic hyperglycemia, insulin 
resistance and β-cell dysfunction typiﬁ  ed by loss of early (ﬁ  rst-phase) insulin secre-
tion (Weyer et al 1999). Chronic hyperglycemia is an established risk factor for the 
micro- and macrovascular complications associated with T2DM and especially for 
cardiovascular disease-the major cause of morbidity and mortality in subjects with 
diabetes (Lee et al 2000; Stratton et al 2000). However, epidemiological studies 
around the world have demonstrated a hidden risk factor associated with the overall 
diabetic mortality; in respect postprandial hyperglycemia (Khaw et al 2001). Indeed, 
the Diabetes Epidemiology Collaborative analyses of Diagnostic Criteria in Europe 
and Asia concluded that 2-hour postprandial plasma glucose levels (PPG) is a better 
predictor of premature death than fasting plasma glucose (FPG) (DECODE Study 
Group 2001; Nakagami and DECODE Study Group 2004).
Nowadays, postprandial hyperglycemia is widely recognised as the central feature 
of early diabetes and impaired glucose tolerance (IGT) (Home 2005). Postprandial 
hyperglycemia is caused primarily by the impairment of ﬁ  rst-phase insulin secretion 
and the correction of this defect is an important determinant of long-term glycemic Vascular Health and Risk Management 2007:3(6) 798
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control (Dinneen 1995). It contributes signiﬁ  cantly to the 
process of T2DM and, if uncontrolled, is an independent 
risk factor for macrovascular complications and associ-
ated mortality (Fonseca 2003). Moreover, as assessed by 
an ongoing clinical trial on the efﬁ  cacy of nateglinide on 
prevention of T2DM in high-risk patients and cardiovascular 
outcomes, IGT may go undiagnosed in up to 31% of middle-
aged patients at risk of developing cardiovascular diseases 
(Califf on behalf of the NAVIGATOR Trial Group 2003). 
Accordingly, the control of postprandial hyperglycemia is 
emerging as an important component of diabetes manage-
ment (Ceriello 2005; Davies 2005).
In the normal individual the pancreatic β-cell responds 
in a biphasic manner to insulin secretagogues (such as 
glucose and amino acids). Essentially there is an early 
burst of insulin release within the initial 10 minutes and 
a second-phase characterized by a progressive increase in 
insulin secretion lasting up to several hours (Gavin 2001). 
The early burst of insulin secretion is critically important 
as it plays an important role in priming target tissues of 
insulin, especially the liver, responsible for normal glucose 
homeostasis following food uptake (Bratanova-Tochkova 
et al 2002). The loss of ﬁ  rst-phase insulin secretion in 
response to glucose occurs relatively early in the develop-
ment of T2DM and the early impairment of the functional 
integrity of plasma incretins, ie, glucagon-like peptide 1 
(GLP-1) and gastric inhibitory peptide (GIP), has a major 
contribution to the β-cell deterioration and failure to sup-
press glucagon release post-meal (Laferrère et al 2007). 
As a result, an excessive prolonged insulin release from 
the pancreas will manage to eventually return glucose 
levels back to normal. Therefore, the patient is obligated 
to experience a prolonged period of hyperglycemia and 
hyperinsulinemia (Del Prato 2003).
Nateglinide is an insulinotropic agent that restores the 
physiological pattern of insulin secretion lost in T2DM in a 
transient and glucose-sensitive manner and thus can control 
glucose mealtime excursions. Nateglinide can be used in 
monotherapy, in order to control excessive mealtime glucose 
spikes early in the development of diabetes, or in combina-
tion with other agents that have complementary modes of 
action, such as metformin or glitazones, thus providing better 
overall chronic glycemic control by reducing HbA1c (Dunn 
and Faulds 2000).
In this review, we present data on the role of nateglinide 
as the “gate-keeper” of insulin secretion’s early phase and 
additionally why and when to use such an early-phase insu-
lin secretion agent in the treatment of T2DM. Moreover, 
ongoing data on its role in the management of prediabetes 
state are discussed.
Nateglinide and its effect on insulin 
secretory pathways
The exact mechanism by which insulin release is regulated 
to achieve euglycemia has not been completely established. 
However, pancreatic β-cells do respond to extracellular glu-
cose through the generation of adenosine triphosphate (ATP) 
and the actions of ATP-sensitive KATP and voltage sensitive 
L-type Ca2+ channels in the β-cell membrane. Normally, 
ATP inhibits ATP-sensitive K+ (KATP) channels, causing cell 
depolarization and the opening of voltage-dependent Ca2+ 
channels. As a result, the inﬂ  ux of Ca2+ triggers exocytosis 
and insulin release (McClenaghan et al 1999). KATP chan-
nels compromise a pore of inwardly rectifying K+ channel 
subunits encased by sulfonylurea receptor subunits (SURs) 
with ATP-ase activity. Nateglinide binds competitively to 
SURs, thereby inhibiting KATP channels (Hu 2002). The 
interaction between nateglinide and KATP channels causes 
local depolarization of the plasma membrane. This is fol-
lowed by an inﬂ  ux of calcium through the opening of the 
L-type Ca2+ channels and the stimulation of insulin secretion 
(Uto et al 2002).
Differences in the interactions with the KATP channels can 
potentially explain in part the contrasting pharmacological 
properties of each insulinotropic agent. In vitro, as well 
as in vivo studies have indicated that the plasma proﬁ  les 
for insulin secretion following administration of either 
repaglinide or glibenclamide are not reminiscent of the 
physiological patterns of insulin secretion (Laghmich et al 
1999). They are characterized by a longer duration of action 
that produces a prolonged insulin secretion, which in its 
turn effectively reduces the ability of the pancreatic β-cell 
to mediate a moment-by-moment response to changes in 
blood glucose. Furthermore, this reduced responsiveness of 
the glucose feedback control system is handicapped by the 
relative insensitivity of both repaglinide and glibenclamide to 
glycemic status; the stimulation of insulin secretion is similar 
at low or high glucose levels (Hu et al 2000).
Nateglinide, as indicated by comparative studies, inhibits 
KATP channels more rapidly and with a shorter duration of 
action than both repaglinide and glibenclamide. This may be 
due to its greater degree of speciﬁ  ty for SUR1 over SUR2 
receptors and the reduction of sustained depletion of islet 
cell insulin compared with sulfonylureas (Ball et al 2000). 
In addition, the short duration of action of nateglinide is 
glucose-dependent. The response of the KATP channel to Vascular Health and Risk Management 2007:3(6) 799
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nateglinide is markedly lower during periods of euglycemia 
than at higher glucose concentrations. As nateglinide does not 
induce prolonged insulin release, it reduces the stress on the 
β-cell by eliminating the need for almost continuous insulin 
secretion. The clinical consequence of its short duration of 
action and its sensitivity to glycemic status is the decreased 
risk of hypoglycemia and potential pancreatic β-cell damage. 
Nateglinide has also been shown to enhance β-cell sensitivity 
to glucose in animal models without affecting basal insulin 
secretion. These preliminary observations support the view 
that, by increasing sensitivity to glucose, nateglinide may 
allow islet β-cells to avoid the unfavorable effects of chronic 
hyperinsulinemia (Ball et al 2004).
Lately, nateglinide has been reported to present a direct 
effect upon exocytosis of insulin independent of KATP chan-
nel function in the plasma membrane. This is achieved by 
targeting intracellular sites in the absence of KATP channel 
function. In this point of view, nateglinide has been shown to 
stimulate directly growth hormone exocytosis in rat pituitary 
cells and glucagon as well as insulin in pancreatic a- and 
β-cells, respectively (Bokvist et al 1998, 1999; Gromada 
et al 2002). This KATP channel-independent effect of nateg-
linide is increasingly thought to play an important role in the 
regulation of second-phase insulin secretion, which could 
provide considerable beneﬁ  ts in the therapy of subjects with 
T2DM. Most importantly, these effects of nateglinide were 
not accompanied by appreciable decline in cell viability or 
cellular insulin content (Maedler et al 2005). In conclusion, 
it may be sustained that nateglinide potentiates initiation and 
augmentation pathways for glucose-induced insulin release, 
suggesting likely effectiveness on both ﬁ  rst- and second-
phase insulin secretions.
Besides these beneﬁ  ts, nateglinide shows enhanced 
activity in an experimental in vitro model of the metabolic 
abnormalities associated with T2DM (ie, ATP depletion and 
the uncoupling of oxidative phosphorylation). The potency 
of nateglinide was increased by approximately 400-fold 
under these conditions, while the potency of glimepiride 
was increased 13-fold, that of glibenclamide was unchanged 
and that of repaglinide was decreased 10-fold (Hansen 
et al 2002). This implies that the structural determinants 
involved in nateglinide binding overlap with those of sulfo-
nylureas. In contrast, the properties of repaglinide binding 
and inhibition differ from those of the sulfonylureas. This 
is of relevance in terms of other known differences in the 
mechanism of action of repaglinide and that of other insulin 
secretagogues. It is possible, although unproven, that the 
shared characteristics of the binding sites for nateglinide 
and sulfonylureas, demonstrated in this study, may explain 
these differences.
KATP channels subtypes are found not only in pancreatic 
β-cells, but also in coronary blood vessels (where they 
regulate coronary blood ﬂ  ow), in cardiomyocytes (where 
they aid the adaptation of the heart to ischemic stress) and 
in mitochondria (where they appear to help to “precondi-
tion” the heart to cope with prolonged ischemia). Thus, it 
is obvious that a further concern with therapeutic agents 
that inﬂ  uence KATP channels is their potential for affecting 
cardiac function. Patch-clamp techniques have been used to 
investigate the tissue selectivity of nateglinide for cardiac, 
β- and aortic cells in comparison with glibenclamide and 
repaglinide (Akiyoshi et al 1995; Hu et al 1999). Nateglinide 
demonstrates a signiﬁ  cant degree of selectivity (up to 1000-
fold) for the pancreatic KATP subtype over the vascular and 
the cardiac subtype (Chachin et al 2003). Glibenclamide 
shows only moderate pancreatic selectivity (10 to 20-fold) 
and repaglinide is non-selective (2-fold). In other words, 
in contrast to repaglinide and glibenclamide, nateglinide 
would be less likely to cause detrimental cardiac effects 
via blockade of cardiovascular KATP channels than either 
of these agents. The selectivity of nateglinide for pancre-
atic KATP channels may confer additional advantages with 
regard to cardiovascular outcomes in patients with T2DM 
(Quast et al 2004).
Nateglinide pharmacokinetics
The molecule of nateglinide has a number of unique phar-
macokinetic properties that contribute to its clinical utility 
in T2DM. First, it is rapidly and extensively absorbed from 
the small intestine after oral administration. Clinical studies 
in subjects with T2DM show absorption of nateglinide to 
be almost complete (90%) after oral administration, while 
its mean absolute bioavailability is estimated to be approxi-
mately 72%, indicating a modest ﬁ  rst pass effect (McLeod 
2004). A dose proportional (30–180 mg) rise in plasma levels 
follows oral administration with plasma concentrations peak-
ing at approximately 1 hour post dose (Gribble 2001).
Although fasting status does not have a signiﬁ  cant effect 
on overall plasma exposure, the existing data indicate that 
nateglinide should be administered before meals to maximize 
the rate of absorption (Kalbag et al 2000; Luzio et al 2001). 
The absorption proﬁ  le of nateglinide does not appear to be 
signiﬁ  cantly affected by meal composition and its plasma 
concentration-time curves are similar when administered 
shortly before a high fat, carbohydrate or protein meal 
(Karara et al 1999; Keilson et al 2000).Vascular Health and Risk Management 2007:3(6) 800
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Nateglinide is extensively bound non-speciﬁ  cally to plasma 
proteins (primarily serum albumin) in the systemic circulation 
(98%) and is distributed throughout the body. In vitro studies 
using nateglinide with a broad spectrum of drugs (furosemide, 
propranolol, captopril, nicardipine, pravastatin, glibenclamide, 
warfarin, phenytoin, acetylsalicylic acid, tolbutamide or met-
formin) showed no binding interaction, suggesting a low poten-
tial for drug to drug interactions (Keilson et al 2000). However, 
the extensive binding to plasma proteins restricts distribution 
of nateglinide beyond the plasma volume, as indicated by the 
relatively low volume of distribution at steady state.
Nateglinide undergoes extensive metabolism prior to excre-
tion. Less than 8% of unchanged drug is being excreted and 
its metabolites are rapidly eliminated with the major route of 
elimination being renal (∼85% of dose) (Takesada et al 1996). 
There is no evidence for the accumulation of nateglinide or for 
any of its metabolites within the body (Weaver et al 2001).
Nateglinide pharmacodynamics
Pharmacodynamic studies in subjects with T2DM have 
demonstrated that the administration of nateglinide induces 
endogenous early phase insulin secretion in a physiological 
manner comparable with a bolus insulin dose. As the effect of 
nateglinide is speciﬁ  c to prandial insulin secretion, additional 
reductions in HbA1c may be achieved without risking the 
occurrence of hypoglycemic events between meals (Carroll 
et al 2002, 2003). The second phase of insulin release still 
occurs with nateglinide; however there is no extended insulin 
secretion (Barnett et al 2004).
An innovative, continuous method of plasma glucose 
measurement was recently used to evaluate nateglinide. 
Eighteen subjects with T2DM were monitored before and 
after 3 days of treatment with nateglinide which signiﬁ  cantly 
reduced postprandial hyperglycemia following each meal 
and in addition lowered mean FPG levels (Abrahamian et al 
2004). In subjects with IGT, a single-dose administration of 
nateglinide reduced postprandial hyperglycemia, without 
changing the area under the time–concentration curve of 
insulin secretion (Hirose et al 2002). Nateglinide may also 
improve insulin resistance, as measured by the homeostasis 
insulin resistance model, depending upon the degree of 
baseline insulin resistance (Shiba 2003).
Several studies have compared the pharmacodynamic 
effects of nateglinide and other insulin secretagogues. The 
efﬁ  cacy of repaglinide and nateglinide in FPG, PPG excur-
sion and early-phase insulin secretion was found to be similar, 
although the effect of repaglinide on HbA1c was stronger 
than that of nateglinide (Li et al 2007). Both nateglinide and 
repaglinide comparably improve insulin sensitivity and β-cell 
function but nateglinide achieves it with lower total insulin 
exposure (Hollander et al 2001; Abletshauser et al 2005).
The acute effect of nateglinide, glibenclamide and 
placebo on prandial plasma glucose, serum insulin, and 
C-peptide and glucagon excursions was studied in 15 subjects 
with maturity-onset diabetes of the young type 3 (MODY3). 
MODY3 is characterized by a defective insulin response to 
glucose and hypersensitivity to sulfonylureas. A low dose of 
nateglinide prevented the acute postprandial rise in glucose 
more efﬁ  ciently and with less stimulation of peak insulin 
concentrations and hypoglycemic symptoms. Moreover, 
exercise did not induce hypoglycemia after nateglinide 
administration (Tinamaja et al 2006).
In a double-blind, multicenter study subjects with inad-
equate glucose control on maximal doses of metformin were 
randomized to additionally receive nateglinide or gliclazide. 
The nateglinide combination demonstrated better PPG 
control and the reduction from baseline in maximum PPG 
excursion was statistically signiﬁ  cant in the nateglinide group 
only. Postprandial insulin levels were signiﬁ  cantly higher 
with nateglinide (Ristic et al 2006). Α study in drug-naïve 
patients given either nateglinide/metformin or glibenclamide/
metformin combination treatment showed lower PPG excur-
sions with nateglinide, while FPG concentrations were better 
with glibenclamide (Gerich et al 2005).
Control of body weight seems to be easier with nateglinide 
and in several studies, no signiﬁ  cant increase in body weight was 
observed in patients treated with nateglinide despite the improved 
metabolic control. This was also valid when nateglinide was 
compared with metformin therapy (Fuchtenbusch et al 2000).
In subjects with T2DM, postprandial hypertriglyceridemia 
independently increases the risk of atherosclerosis, even in the 
presence of normal fasting triglyceride levels (Teno et al 2000). 
An acute effect of glibenclamide administration in humans 
demonstrated a reduction in total triglycerides and in triglycer-
ides of intestinal origin (Skrapari et al 2001). Acute nateglinide-
in comparison with glibenclamide-administration resulted in a 
greater suppression of postprandial lipemia in rats (Mine et al 
2002) and in humans with T2DM (Mori et al 2004).
Data indicate that the suppression of postprandial non-
esteriﬁ  ed fatty acid levels during acute and chronic treatment 
with nateglinide results from the inhibition of endogenous 
lipolysis or lipid oxidation and lipogenesis (Dimitriadis et al 
2004; Ceriello et al 2004). These effects on lipid proﬁ  les 
might contribute to an anti-atherogenic effect of nateglinide. 
A single dose of nateglinide was found to improve not only 
postprandial glycemia but also coagulation and ﬁ  brinolytic Vascular Health and Risk Management 2007:3(6) 801
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activity in subjects with T2DM. This combined effect, if 
conﬁ  rmed by a long-term study, might reduce cardiovascular 
risk in T2DM (Tentolouris et al 2005). Early insulin secre-
tion following nateglinide administration can also suppress 
postprandial lipemia in subjects with newly diagnosed T2DM 
and improvements in insulin resistance over a short period of 
time seem to exert substantial inﬂ  uence on lipid parameters 
(Masumi et al 2006). Nateglinide not only ameliorates insulin 
resistance as well as insulin secretory defects but it decreases 
daily C-peptide excretion rate as well (Hazama et al 2006).
Nateglinide improves endothelial dysfunction in the post-
prandial state. This effect on endothelium may be important 
in the prevention of atherosclerosis in T2DM. A single dose 
of nateglinide administrated in subjects with T2DM abolished 
the deleterious effects of hyperglycemia on endothelial func-
tion (Shimabukuro et al 2004). However, further studies are 
needed to indicate that nateglinide ameliorates postprandial 
endothelial dysfunction in subjects with insulin resistance 
and to demonstrate the importance of postprandial metabolic 
regulation in the prevention of atherosclerosis.
Fasting versus postprandial 
hyperglycemia
The United Kingdom Prospective Diabetes Study (UKPDS 
33 1998; UKPDS 49 1999) was the landmark study clearly 
to show that glycemic control is important for the preven-
tion of micro- and macro-vascular complications in patients 
with T2DM. Postprandial hyperglycemic peaks seem to be 
prospective determinants of vascular damage in early T2DM, 
which can be prevented by improved glucose control in con-
junction with adequate control of blood pressure and lipids. 
Thus, reaching a near-normal glycemic target is critically 
important (Standl et al 1996).
Although, the relationship between HbA1c and FPG as 
well as PPG is still controversial, postprandial hyperglycemia 
contributes to HbA1c values in subjects with T2DM, espe-
cially in patients with acceptable glycemic control (Monnier 
et al 2006 and Caputo et al 2001). In the UKPDS although 
concentrations of FPG were maintained over more than 5 
years during the study, HbA1c showed a steady increase year 
after year. This indicates that control of FPG is insufﬁ  cient 
to control HbA1c and that PPG peaks are a major source for 
HbA1c (UKPDS 49, 1999; Dimitriades et al 2004).
In the Diabetes Mellitus, Insulin Glucose Infusion in 
Acute Myocardial Infarction (DIGAMI) study (Malmberg 
et al 1999), mortality after myocardial infarction was reduced 
with aggressive hypoglycemic treatment with insulin. Dif-
ferences in glucose concentrations were associated with 
differences in HbA1c. Moreover, the normalization of blood 
glucose levels with insulin therapy improved the prognosis 
in critically ill patients, even if they did not previously had 
diabetes (Van den Berghe et al 2001). In conclusion, if pre-
vention of macrovascular complications and HbA1c values 
near normal (ie, 6.5%) are the goals of therapy, a good 
rationale for adequate control of postprandial hyperglycemia 
in diabetic patients should exist.
The UKPDS has substantiated that the loss of endog-
enous insulin secretion is the cause of the progression of 
T2DM. However, early insulinization was not advantageous 
over other forms of therapy. In recent years, the advent 
of polypharmacy has greatly strengthened the treatment 
of diabetes. Development of medications restoring early 
phase insulin-secretory defects is of clinical relevance in 
the managements of T2DM (American Diabetes Association 
2001). Nateglinide can be used to reduce mealtime glucose 
excursions and HbA1c as monotherapy and in combination 
with metformin; its antidiabetic potential is similar to the 
combination treatment with glibenclamide and metformin. 
Additional substantiation of its long-term effect on improv-
ing life expectancy and reducing diabetic complications in 
subjects with T2DM is required (European Diabetes Policy 
Group 1999). HbA1c is the gold standard for assessing the 
impact of glucose control in terms of the occurrence and 
prevention of diabetic complications (Standl et al 2000). The 
DECODE study in Europe has indicated that in the context 
of HbA1c higher glucose excursions are a strikingly stronger 
predictor of cardiovascular risk than fasting hyperglycemia 
(DECODE study group 1999a, 1999b).
Metabolic phenotypes
Pharmacotherapy of subjects with T2DM is much individu-
alized. The logical way to tailor antidiabetic therapy to the 
personal needs of subjects with T2DM and to ensure the best 
quality of life is to deliberate the disadvantages of pharmaco-
therapy on the one hand and to asses the speciﬁ  c metabolic 
characteristics of the individual patient on the other. In T2DM, 
four major metabolic phenotypes can be differentiated: post-
prandial versus fasting hyperglycemia, and insulin resistance 
versus insulin deﬁ  ciency. However, the metabolic phenotype 
can alter along with the development and progression of the 
diabetes (American Diabetes Association 2005).
If the diagnosis is not delayed for years, T2DM often 
emerges predominantly as a postprandial disease. As a result, 
fasting hyperglycemia mostly points to a more advanced 
stage of insulin deﬁ  ciency and a markedly increased hepatic 
glucose output. Insulin deﬁ  ciency is particularly prominent Vascular Health and Risk Management 2007:3(6) 802
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during the early phase of insulin secretion, leading to an insuf-
ﬁ  cient suppression of hepatic glucose output after a meal and, 
hence, to postprandial hyperglycemia (Mitrakou et al 1992).
Insulin resistance seems to be a lifelong key problem 
in many patients with T2DM, even under treatment with 
insulin, and is aggravated by the modiﬁ  able factors of central 
obesity and physical inactivity. Insulin resistance is widely 
envisaged as the underlying denominator of the metabolic 
risk network consisting of hyperglycemia, hypertension and 
dyslipidemia (Reaven 1988).
Current treatment approaches
to T2DM management
In the UKPDS (UKPDS 49 1999), loss of endogenous insulin 
secretion has been substantiated to cause the progression of 
T2DM and the reaching of a near-normal glycemic target is the 
golden goal, irrespective of the mode of therapy. The overall 
conclusion from this study was to treat T2DM as early as pos-
sible, and to escalate therapy, however, to more aggressively 
keep pace with the progressive disease, and take the use of 
insulin into consideration. The recent consensus statement by 
the American Diabetes Association and the European Associa-
tion for the Study of Diabetes suggests initiation of metformin 
together with lifestyle changes as initial therapeutic approach 
to patients with T2DM (Nathan et al 2006). However, addi-
tion of either insulin secretagogues or glitazones or insulin 
is suggested when the HBA1c goal is above 7%. The greatest 
advance in the treatment of T2DM in recent years is the advent 
of polypharmacy, initially suggested by the UKPDS. This 
synergy has been strengthened of late with the development of 
early-phase insulin secretion agents (Yki-Jarvinen 2000).
Modes to select antidiabetic 
drug treatment
The appropriate antidiabetic combination therapy is selected 
when the pros and cons of the available options are estimated in 
relation to the individual patient’s coexisting morbidity, meta-
bolic situation and preferred lifestyle. The therapy of choice is 
frequently based on the early combination therapy and the major 
determinants are body weight, the risk of hypoglycemia, and 
renal as well as cardiopulmonary function including heart failure 
(DeFronzo 2000). The stage of diabetes with its metabolic phe-
notype may inﬂ  uence the decision on the choice of therapy.
Antidiabetic regimens targeting mealtime hyperglycemia 
are a valuable monotherapy for early stages of glucose intol-
erance, or a constructive add-in treatment for later stages, 
delaying or even preventing the deterioration of β-cell func-
tion in the ﬁ  rst instance and achieving optimum glycemic 
control. Enhancers of early-phase insulin secretion, short-
acting insulinotropic agents, alpha glucosidase inhibitors, 
and rapid-acting insulin are already in use for the control of 
postprandial glycemia.
Current recommendations suggest starting combination 
therapy early, to maximize efﬁ  cacy and to minimize side 
effects. This approach is suggested by the fact that type 2 
diabetes results from a combination of both insulin resistance 
and insulin secretory defect. Additionally, antidiabetic drugs 
do not have a linear dose-effect relation; a medium dose of any 
antidiabetic agent will typically provide 70% to 80% of the 
maximum blood glucose lowering effect. Based on this notion, 
it is preferable to look for a synergistic combination therapy 
in case a medium dose monotherapy can not sufﬁ  ciently reach 
the glycemic target, instead of titrating to effect resulting in a 
greater potential for side effects (Standl 1996).
Clinical efﬁ  cacy of nateglinide
Nateglinide in preventing T2DM
A multicenter, double-blind, randomized study evaluated the 
metabolic effectiveness, safety and tolerability of nateglinide 
and identiﬁ  ed a dose appropriate for use in a total of 288 
subjects with IGT. Subjects received nateglinide (30, 60, 
and 120 mg) or placebo before each main meal. Metabolic 
effectiveness was assessed before and after an 8-week treat-
ment and all adverse events were recorded. Nateglinide was 
safe and effective in reducing postprandial hyperglycemia 
in subjects with IGT. It concluded that, preprandial doses 
of 30 or 60 mg nateglinide can be considered appropriate to 
use for longer-term studies in order to determine whether a 
rapid-onset and reversible, insulinotropic agent can delay or 
even prevent the development of T2DM without raising the 
risk of hypoglycemia (Saloranta et al 2002).
The global NAVIGATOR (Nateglinide And Valsartan 
in Impaired Glucose Tolerance Outcomes Research) trial 
evaluates strategies to reduce or delay progression to diabe-
tes and cardiovascular disease (CVD) in people with IGT. 
Its randomization is to nateglinide 60 mg versus valsartan 
160 mg/day, versus both, versus neither. The study is carried 
out in two phases. In the ﬁ  rst phase, designed to run for three 
years after the last subject is enrolled, the effect of nateglinide 
and valsartan on progression to diabetes will be evaluated. 
In the second, or ’extension’ phase, the drugs’ effects on 
cardiovascular disease will be evaluated. It is designed to 
study approximately 9,000 patients for up to 5 years. The 
end point for this trial is cardiovascular events, as well as 
conversion to diabetes (Callif on behalf of the NAVIGATOR 
Trial Group 2003).Vascular Health and Risk Management 2007:3(6) 803
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The NAVIGATOR trial has already shown that an 
automatic assessment of glycemic status may improve 
unrecognized detection of IGT in people with risk factors 
for heart disease. During the initial screening of 43,509 
subjects with the oral glucose tolerance test (OGTT) 37.5% 
had normal glucose tolerance (NGT), 12.2% had isolated 
impaired fasting glucose, 28.3% had isolated IGT and 22.0% 
had unrecognised diabetes. Retrospective analyses of studies 
using angiotensin converting enzyme (ACE) inhibitors have 
shown that they can favorably affect cardiovascular event 
rate or conversion to diabetes (Lindholm et al 2002; Strawn 
et al 2000). Data from the Decode Study Group has shown 
a strong association between postprandial glucose levels and 
cardiovascular event rates (DECODE Study Group 2001). 
This association has been noted across the spectrum of fast-
ing blood sugars from the euglycemic to the diabetic range. 
Furthermore, it has been recently reported that treatment 
of insulin-resistant subjects with acarbose, a glucosidase 
inhibitor that interferes with glucose absorption and targets 
postprandial glycemia, is associated with a signiﬁ  cant reduc-
tion in CVD (Chiasson et al 2003).
The NAVIGATOR trial is the only study powered to 
examine directly the potential for reducing the risk of CVD in 
addition to decreasing the risk of developing T2DM. There is 
an urgent need for a large-scale prevention program to target 
those people who have been identiﬁ  ed as being at high risk 
of CVD and diabetes (Mazzone 2004). The ﬁ  nal analysis of 
primary CVD events is expected to occur late in 2007, and it 
is anticipated that the results will be available in 2008.
Nateglinide in the management
of   T2DM
Patients suitable for nateglinide monotherapy are treatment-
naïve patients and at an early stage of T2DM. Diabetic sub-
jects with moderately elevated fasting plasma glucose and 
HbA1c levels, obese, elderly or with more severe diabetes, but 
who still have insulin secretion ability can also beneﬁ  t from 
nateglinide monotherapy. Randomized, double-blind con-
trolled trials have shown that nateglinide (120 mg three times 
daily before meals) signiﬁ  cantly improves long-term glycemic 
control in patients with T2DM by reducing HbA1c levels by 
approximately 0.4%–0.8% (Horton et al 2000; Hollander 
et al 2001; Rosenstock et al 2002; Saloranta et al 2002). The 
improvements in overall glycemic control are explained by 
a dose-dependent effect on postprandial glucose excursions. 
Recent analysis from randomized-controlled trials suggests 
that nateglinide can be an alternative oral hypoglycemic agent 
of similar potency to metformin and may be indicated where 
side effects of metformin are intolerable or where metformin 
is contraindicated. However, further data is needed to indicate 
what effect nateglinide will have on important long-term 
outcomes, such as mortality (Black et al 2007).
The efﬁ  cacy and tolerability of the combination of nateg-
linide (120 mg t.i.d.) and metformin (500 mg t.i.d.) as initial 
treatment in drug-naïve patients with T2DM was examined 
in a 24-week trial that compared nateglinide, metformin 
and the combination therapy in 701 patients with baseline 
HbA1cbetween 6.8% and 11.0%. The two agents produced 
equivalent reductions in HbA1c of 0.8% at 24 weeks and had 
an additive effect in combination (Horton et al 2004). Indeed, 
70% of patients treated with nateglinide plus metformin 
achieved an HbA1c level of 7% (Raskin et al 2003). Nat-
eglinide (60 mg or 120 mg t.i.d.) was added to the therapy in 
patients with T2DM (n = 467) who were stabilised on high-
dose metformin (1000 mg twice daily). After 24 weeks, both 
nateglinide doses signiﬁ  cantly reduced HbA1c compared with 
placebo, with the greatest reductions occurring in patients with 
high baseline HbA1c levels (Marre et al 2002).
The effect of nateglinide on efﬁ  cacy, tolerability and safety 
in elderly patients (n = 358) with T2DM (mean age up to 84 
years) on diet alone or on metformin was assessed in a 12-
week, parallel study. Nateglinide (120 mg) was given as either 
monotherapy in patients previously on diet alone or low-dose 
sulfonylureas (group 1) or as an addition therapy in patients 
on steady dose of metformin (group 2). HbA1c fell by a mean 
of 0.83% in group 1 and 0.67% in group 2. Forty four percent 
of patients in the ﬁ  rst group and 34% in the second group 
achieved target of HbA1c 7.0 and 66% in group 1 and 59% 
in group 2 achieved of HbA1c 7.5% (Weaver et al 2002).
A double-blind, parallel, randomized, multicenter study 
compared the effects of nateglinide plus metformin with 
gliclazide plus metformin on glycemic control in patients 
with T2DM. Patients with inadequate glucose control on 
maximal doses of metformin were randomized to additionally 
receive for over 24 weeks nateglinide (n = 133) or gliclazide 
(n = 129). No signiﬁ  cant difference was seen between the two 
groups in terms of HbA1c, the proportion of patients achieving 
a reduction of HbA1c  0.5% or an end point HbA1c 7%. 
The overall rate of hypoglycemia events was similar in 
the nateglinide group compared with the gliclazide group. 
However, the nateglinide combination demonstrated better 
postprandial glucose control and the postprandial insulin 
levels were signiﬁ  cantly higher with nateglinide compared 
with gliclazide (Ristic et al 2006).
A 24-week, multicenter, double-blind, randomized study 
determined the effects of nateglinide added to rosiglitazone Vascular Health and Risk Management 2007:3(6) 804
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monotherapy on glycemic control and on postprandial 
glucose and insulin levels in patients with T2DM. By 
selectively augmenting early insulin release and decreasing 
prandial glucose excursions, nateglinide produced a clini-
cally meaningful improvement in overall glycemic exposure 
in patients with T2DM inadequately controlled with rosi-
glitazone. Therefore, nateglinide substantially improves the 
likelihood of achieving a therapeutic target of HbA1c 7.0% 
(Fonseca et al 2003).
Mathematical model data suggest that although drug 
treatment costs are increased by combination therapy, this 
cost is expected to be partially offset by a reduction in the 
costs of treating long-term diabetes complications (Ward 
et al 2004).
Recently, retrospective subgroup analyses from all 
completed nateglinide studies evaluated the impact of 
renal impairment (estimated creatinine clearance [Clcr] 
60 mL/min per 1.73 m2) and low baseline HbA1c (7.5%) 
on comorbidity in patients with T2DM, and assessed the 
efﬁ  cacy and safety of nateglinide monotherapy in these 
patients and in subgroups of patients over age 64 years with 
or without renal impairment. Nateglinide was effective and 
well tolerated in all treated patients. In subgroups in which 
metformin and long-acting sulfonylureas must be used with 
caution, nateglinide had a low risk of adverse events and 
hypoglycemia (Del Prato et al 2003). Treating renal trans-
plant recipients with nateglinide for two weeks signiﬁ  cantly 
improved postprandial hyperglycemia, increased the insulin 
response following a standardized meal and was well toler-
ated (Voytovich et al 2007).
Recently, the effect of adding nateglinide to therapy 
with insulin glargine in adults (n = 55) with T2DM 
(HbA1c8.2 ± 1.0%), duration of diabetes 12.8 ± 6.0 years, 
duration of insulin treatment 6.0 ± 4.0 years) previously 
treated with insulin and with poor blood glucose control was 
determined in a 16-week, double-blind, placebo-controlled 
study. Addition of nateglinide before meals to once-daily 
insulin glargine in people with long-standing diabetes already 
requiring insulin therapy improved blood glucose control in 
the early part of the day after breakfast and lunch, but did 
not provide good control of blood glucose levels overall 
(Dashora et al 2007).
Conclusion: the position
of an early-phase insulin secretion 
agent in the therapy of   T2DM
Nateglinide, although is chemically distinct from sulfonyl-
ureas, conversely, from a more practical point it has many 
characteristics in common with the latest, as a very rapid 
and most short-acting insulin-releasing agent (Standl et al 
2003). Nateglinide when given to subjects with T2DM 
just before meals decreases mealtime glucose excursions 
which improves overall glycemic control with a minimal 
risk of hypoglycemia. Compared with placebo, HbA1c val-
ues are approximately 1% lower after nateglinide therapy 
(Dornhorst 2001).
This non-sulfonylurea entity seems to be particularly 
appropriate for the control of postprandial hyperglycemia. 
It also, allows a more ﬂ  exible lifestyle and the possibility 
to skip a meal without the risk of hypoglycemia that would 
be experienced with glibenclamide therapy. Conversely, an 
additional meal can be incorporated into the meal plan, pre-
ceded by an extra dose without worsening glycemic control 
(Hanefeld et al 2000).
According to current recommendations, metformin is the 
ﬁ  rst-line therapy in the management of T2DM (American 
Diabetes Association 2006). Nateglinide may be an alterna-
tive option when the use of metformin is not advisable due 
to frequent contraindications and/or side effects (Horton et al 
2000). Nateglinide could also replace favorably sulfonylureas 
in the early phase of T2DM, since nateglinide-induced insu-
lin secretion may manage efﬁ  ciently postprandial glycemia 
(Marre et al 2002).
Moreover, treatment with this insulin secretion agent 
does not incur chronic hyperinsulinemia, which can be 
advantageous in controlling body weight and avoiding the 
burden of otherwise occurring hypoglycemia. Hence, the 
use of nateglinide could be of beneﬁ  t for elderly subjects 
(Weaver et al 2002).
Nateglinide since it does not contain a sulfonylurea 
moiety is also an excellent candidate for early combination 
therapy with other oral agents, in particular with metformin 
or glitazones. The blood glucose-lowering capacity of nat-
eglinide is added to that of these medications and yields an 
overall potential HbA1c reduction of 1.8 to 2.5%. The UKPDS, 
however, has raised some controversy on the usefulness of 
this latter combination, as a result of a reportedly higher rate 
of cardiovascular complications compared with randomly 
maintained monotherapy with glibenclamide. Conversely, 
the cardiovascular complication rate was unusually low in 
the glibenclamide group (Hollander et al 2000).
Nateglinide could also be used in combination with either 
alpha-glucosidase inhibitors or glitazones. The combina-
tion with glitazones was shown to double HbA1c reduction 
compared with repaglinide monotherapy without signiﬁ  cant 
weight gain, in contrast to the excessive weight increase Vascular Health and Risk Management 2007:3(6) 805
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observed with the use of sulfonylureas and glitazones 
(Rosenstock et al 2002; Fonseca et al 2003). Nateglinide 
targets postprandial hyperglycemia via different mechanisms 
and should, therefore, be beneﬁ  cial in combination with 
metformin or glitazones (Moses et al 1999).
In conclusion, the safety and convenience of nateglinide, 
coupled with its selective effect on postprandial hypergly-
cemia, makes it an attractive ﬁ  rst-line, oral hypoglycemic 
monotherapy in newly diagnosed patients with T2DM that 
have near-normal fasting plasma glucose levels, are elderly, 
or who are unable to tolerate other oral hypoglycemic agents. 
It is also effective as combination therapy with metformin 
and glitazones for patients with more advanced disease 
requiring therapy to reduce both fasting and postprandial 
hyperglycemia.
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